


Please type a plus sign (+) inside this box

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/538,829
				Filing Date	March 30, 2000
				First Named Inventor	Pankaj Modi
				Group Art Unit	1646
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	358594-00010-2



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code* (if known)			
Tlu	A	4,948,588		Kamiya et al.	08/14/1990	
	B	5,536,444		Hettche et al.	07/16/1996	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>5</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)				
Tlu	C	WFO	WO99/16417		Flemington Pharmaceutical Corporation	04/08/1999		
	D	PCT	WO00/47203		MQS, Inc.	08/17/2000		

Examiner Signature	<i>[Signature]</i>	Date Considered	3-12-01
--------------------	--------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (10-96)

Please type a plus sign (+) inside this box



Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	09/538,829
				Filing Date	March 30, 2000
				First Named Inventor	Pankaj M. Bhatnagar
				Group Art Unit	1646
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	358594-00010-2

Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Tw	E	B.J. AUNGST and N.J. ROGERS, <i>Comparison of Nasal, Rectal, Buccal, Sublingual and Intramuscular Insulin Efficacy and the Effects of a Bile Salt Absorption Promoter</i> , The Journal of Pharmacology and Experimental Therapeutics, (September 21, 1987), pp. 23-27, Vol. 244, No. 1, The American Society for Pharmacology and Experimental Therapeutics	
	F	B.J. AUNGST and N.J. ROGERS, <i>Site Dependence of Absorption-Promoting Actions of Laureth-9, Na Salicylate, Na<sub>2</sub>EDTA, and Aprotinin on Rectal, Nasal, and Buccal Insulin Delivery</i> , Pharmaceutical Research, (1988), pp. 305-308, Vol. 5, No. 5, Plenum Publishing Corporation.	
	G	B.J. AUNGST and N.J. ROGERS, <i>Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery</i> , International Journal of Pharmaceutics, (1989) pp. 227-235, Vol. 53, Elsevier Science Publishers B.V.	
Tw	H	A.H. SHOJAEI, <i>Buccal Mucosa As a Route for Systemic Drug Delivery: A Review</i> , J Pharm Pharmaceut Sci, (1998), pp. 15-30, Vol. 1(1).	

Examiner Signature		Date Considered	3-12-01
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.